ReviewRheumatology international2020
The lipid paradox in rheumatoid arthritis: the dark horse of the augmented cardiovascular risk.
Review in Rheumatology international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 75 citations in OpenAlex.
- Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment.Annals of the rheumatic diseases · 2024Trial
- Effects of melatonin supplementation on disease activity, oxidative stress, inflammatory, and metabolic parameters in patients with rheumatoid arthritis: a randomized double-blind placebo-controlled trial.Clinical rheumatology · 2021Trial
- Unsupervised machine learning with Cluster Analysis in patients with rheumatoid arthritis: insights in CV risk phenotypes from a multicentre Italian cohort.Internal and emergency medicine · 2026Article
- Review
- A Prediction Model for One-Year Disability Risk Among Community-Dwelling Older Adults in China: Integrating Physical, Metabolic, and Psychosocial Factors.Health care science · 2026Article
- Subclinical atherosclerosis in patients with undifferentiated connective tissue disease: comparison with rheumatoid arthritis.Clinical rheumatology · 2026Article
- [Consensus statement of the Austrian Society for Rheumatology and Rehabilitation on the management of increased cardiovascular risk in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis].Wiener klinische Wochenschrift · 2026Article
- Optimising Conventional Therapy in Rheumatoid Arthritis.Mediterranean journal of rheumatology · 2026Review
- Non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio in relation to erectile dysfunction: a cross-sectional study.Translational andrology and urology · 2026Article
- Lipid parameters and disease activity in rheumatoid arthritis: a cross-sectional analysis of the Kuwait registry for rheumatic diseases (KRRD).Frontiers in medicine · 2026Article
- The SIRT1/STAT3 axis as a central regulator of immune, inflammatory, and lipid metabolic dysregulation in rheumatoid arthritis: therapeutic implications.Frontiers in immunology · 2026Review
- Atherosclerosis features in rheumatic diseases - focus on peripheral artery disease.Frontiers in immunology · 2026Review
- An experimental study of early cardiovascular disease and risk factors in a collagen-induced arthritis rat model.Frontiers in immunology · 2026Article
- Association between low-density lipoprotein cholesterol and frailty in adults aged ≥70 years: a cross-sectional study from Beijing, China.Frontiers in endocrinology · 2026Article
- From joints to vessels: How rheumatoid arthritis therapy alters the fate of the heart.World journal of cardiology · 2025Review
- Article
- Pathophysiological Links Between Inflammatory Bowel Disease and Cardiovascular Disease: The Role of Dysbiosis and Emerging Biomarkers.Biomedicines · 2025Review
- Metabolic and systemic inflammation status in rheumatoid arthritis-fasting blood glucose as a primary predictor of rheumatoid arthritis risk: a cross-sectional study in Iran.Osong public health and research perspectives · 2025Article
- The presumable combined effects of hydroxychloroquine and its metabolites on the blood lipids and glucose in the treatment of rheumatoid arthritis.Inflammopharmacology · 2025Article
- GPIHBP1 increase accounts for rheumatic arthritis-related hypotriglyceridemia by facilitating lipids uptake of white adipose tissues.Arthritis research & therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammation that, if left untreated, can cause joint destruction and physical impairments. The inflammatory process is systematic, and it is associated with increased morbidity and mortality. Over the last years, mortality presents a decreasing trend; still, there is a high burden of cardiovascular disease (CVD) in RA that seems to be related to coronary atherosclerosis. Chronic inflammation, physical inactivity, and drugs used to treat RA are some of the reasons. Thus, the management of CVD risk is essential and involves the patient's stratification using distinct parameters that include assessment of the blood lipid profile. However, 'dyslipidemia' in RA patients follows a different pattern under the impact of inflammatory processes, while therapies that target the underlying disease change the levels of specific lipid components. In this review, we explore the relationship between blood lipids and inflammation in the so-called ΄lipid paradox΄ in RA, and we present the existing knowledge over the influence of antirheumatic drugs on the lipid profile of RA patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.